Why Compugen is a Favorite Biotechnology Firm

Compugen (CGEN) presented its third-quarter achievements and financial results. We believe the firm is on the right track towards clinically confirming that its discovered targets, PVRIG and TIGIT when inhibited, will extend the capability of the current checkpoint inhibitors into treating cancers resistant to immunotherapy by checkpoint inhibition.  
From Compugen
Anat Cohen-Dayag, Ph.D., President and CEO of Compugen . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.